U.S., Nov. 27 -- ClinicalTrials.gov registry received information related to the study (NCT07251608) titled 'Randomized, Open-label, Safety Study of Subcutaneous and Intramuscular Injections of Niagen(R) Plus' on Nov. 03.
Brief Summary: The goal of this study is to learn about the safety of Niagen(R)Plus, an injectable form of nicotinamide riboside (NR), and to see how it affects levels of NAD+ in the blood. Niagen(R)Plus will be given either by subcutaneous (under the skin) or intramuscular (into the muscle) injection at two dose levels (50 mg or 100 mg).
The main questions this study aims to answer are:
Is Niagen(R)Plus safe and well-tolerated when given by injection several times over 100 days?
How do NAD+ levels in blood change afte...